AF anticoagulation
Reading File
Finding Sources
Searching PubMed
"atrial fibrillation"[MeSH Terms] AND "anticoagulants"[MeSH Terms]
Searching the Web
AF anticoagulation guidelines 2025 CHA2DS2-VASc DOAC
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
I now have comprehensive material. Here is a structured reference on AF anticoagulation:
Atrial Fibrillation: Anticoagulation
1. Why Anticoagulate?
AF accounts for ~15–20% of all ischemic strokes. The thrombus forms predominantly (≈90%) in the left atrial appendage (LAA). Anticoagulation reduces overall stroke risk by nearly 70% but carries an increased risk of major bleeding — so net benefit must always be weighed individually. - Rosen's Emergency Medicine, p. ~2165; Harrison's 22e, p. 3494
2. Stroke Risk Stratification: CHA₂DS₂-VASc
| Letter | Risk Factor | Points |
|---|---|---|
| C | Congestive heart failure | 1 |
| H | Hypertension | 1 |
| A₂ | Age ≥ 75 years | 2 |
| D | Diabetes mellitus | 1 |
| S₂ | Prior Stroke / TIA / thromboembolism | 2 |
| V | Vascular disease (MI, PAD, aortic plaque) | 1 |
| A | Age 65–74 years | 1 |
| Sc | Sex category (female) | 1 |
Maximum = 9 points
| Score | Annual Stroke Risk (no anticoagulation) |
|---|---|
| 0 | 0% |
| 1 | 1.3% |
| 2 | 2.2% |
| 3 | 3.2% |
| 4 | 4.0% |
| 5 | 6.7% |
| 6 | 9.8% |
| 7–9 | 9.6–15.2% |
Washington Manual of Medical Therapeutics
Note: The 2024 ESC guidelines adopted the simplified CHA₂DS₂-VA score, removing sex as a standalone risk factor. This reflects new evidence that female sex alone does not independently confer stroke risk in some populations. - MDCalc / ESC 2024
3. ACC/AHA Anticoagulation Recommendations (Nonvalvular AF)
| CHA₂DS₂-VASc | Recommendation |
|---|---|
| 0 (men) / 1 (women) | Antithrombotic therapy can be omitted (Class IIa) |
| 1 (men) / 2 (women) | Oral anticoagulation may be considered (Class IIb) |
| ≥2 (men) / ≥3 (women) | Oral anticoagulation recommended (Class I) |
- Miller's Anesthesia 10e, p. 3928; Washington Manual
Special situations:
- Valvular AF (rheumatic mitral stenosis, mechanical heart valves): DOACs are not appropriate — use warfarin (INR 2–3).
- Rheumatic AF: High stroke risk; warfarin long-term, DOACs not studied.
- Post-MI with AF: Anticoagulate for ≥3 months; continue long-term if AF persists.
4. DOAC vs. Warfarin
DOACs are preferred over warfarin for nonvalvular AF in eligible patients. - Washington Manual
| Drug | Mechanism | Key Notes |
|---|---|---|
| Apixaban (Eliquis) | Factor Xa inhibitor | 5 mg BD; reduce to 2.5 mg BD if ≥2 of: age >80, weight <60 kg, Cr ≥133 µmol/L; lowest GI bleed risk |
| Rivaroxaban (Xarelto) | Factor Xa inhibitor | 20 mg OD with evening meal |
| Edoxaban (Savaysa) | Factor Xa inhibitor | Avoid if CrCl >95 mL/min (↓efficacy) |
| Dabigatran (Pradaxa) | Direct thrombin inhibitor | 150 mg BD (or 110 mg BD if high bleed risk); ~80% renal excretion; reversal: idarucizumab |
| Warfarin | Vitamin K antagonist | INR 2–3; multiple drug/food interactions; reversal: FFP, PCC, vitamin K |
DOAC advantages over warfarin:
- No routine INR monitoring
- Fewer drug/food interactions
- Lower risk of intracranial hemorrhage
- Predictable pharmacokinetics
- Xa inhibitor reversal: andexanet alfa
Harrison's 22e, p. 3494–3495
5. Bleeding Risk Assessment: HAS-BLED
| Letter | Risk Factor | Points |
|---|---|---|
| H | Uncontrolled Hypertension (SBP >160) | 1 |
| A | Abnormal renal or liver function | 1–2 |
| S | Stroke history | 1 |
| B | Bleeding history or predisposition | 1 |
| L | Labile INR (TTR <60%) | 1 |
| E | Elderly (age >65) | 1 |
| D | Drugs (antiplatelets, NSAIDs) or alcohol | 1–2 |
Score ≥3 = high bleeding risk. The HAS-BLED score should prompt correction of modifiable bleeding risk factors (BP control, avoid NSAIDs, reduce alcohol) — it should not be used to withhold anticoagulation when stroke risk is high. - Rosen's EM; Textbook of Family Medicine 9e
6. Anticoagulation Around Cardioversion
- AF duration < 48 hours (or therapeutic anticoagulation already in place): cardioversion is safe without prior anticoagulation.
- AF duration > 48 hours or unknown: anticoagulate for 3–4 weeks prior, then cardiovert. Alternatively, perform TEE to exclude LAA thrombus before early cardioversion.
- Post-cardioversion: Continue anticoagulation for ≥4 weeks regardless of outcome (risk of "atrial stunning" → thromboembolism).
- If CHA₂DS₂-VASc warrants it, continue indefinitely. - Tintinalli's EM; Rosen's EM
7. Anticoagulation in CKD / Dialysis
- CKD (mild–moderate): DOACs preferred over warfarin; use agents with lower renal excretion (apixaban, rivaroxaban, edoxaban <50% renal) with appropriate dose adjustment. - Brenner & Rector's The Kidney
- ESKD / Dialysis: Warfarin benefit-risk ratio uncertain; conflict exists between guidelines (KDIGO and Canadian Cardiovascular Society recommend against; AHA/ACC suggest warfarin if CHA₂DS₂-VASc ≥2). Apixaban increasingly used but limited RCT data. - Brenner & Rector's The Kidney, p. 2333–2335
8. AF + Coronary Artery Disease / PCI ("Triple Therapy")
- After PCI in AF: combine oral anticoagulant (preferably DOAC) with P2Y₁₂ inhibitor (clopidogrel preferred over ticagrelor/prasugrel).
- Triple therapy (OAC + aspirin + P2Y₁₂) for up to 30 days in high ischemic risk (e.g., ACS); strongly increases bleeding risk.
- Beyond 30 days: transition to OAC + single antiplatelet or OAC alone. - Harrison's 22e, p. 3495
9. Left Atrial Appendage Closure (LAAC)
For patients with high thromboembolism risk but serious bleeding risk preventing long-term anticoagulation:
- Watchman device (percutaneous endocardial occlusion): noninferior to warfarin; significant reductions in major bleeding, hemorrhagic stroke, and all-cause mortality versus warfarin; noninferior to DOACs in preventing major cardiovascular/neurologic/bleeding events.
- Surgical LAA excision/ligation: can be combined with atrial maze surgery. - Harrison's 22e, p. 3494; Braunwald's Heart Disease
10. Perioperative Anticoagulation Management
- Warfarin: Stop 4–5 days before procedure. Bridging (with LMWH/UFH) is now generally reserved for very high-risk patients (mechanical mitral valves, very high CHA₂DS₂-VASc); the BRIDGE trial showed no benefit of bridging for most AF patients.
- DOACs: No bridging required. Hold based on renal function and procedure bleeding risk (typically 1–2 days for low-bleed-risk, 3–5 days for high-bleed-risk procedures). - Washington Manual; Miller's Anesthesia 10e
Recent Evidence (2024–2025)
- Timing of DOAC initiation after acute ischemic stroke in AF: The CATALYST IPD meta-analysis (Lancet 2025, PMID 40570866) is the definitive study. Earlier initiation (≤4 days) appears safe and effective — watch for updates to guidelines.
- AF + stable CAD: Meta-analysis in JACC 2025 (PMID 39918465) supports OAC monotherapy (without antiplatelet) after the initial post-PCI period in stable disease.
Key practice summary:
- Calculate CHA₂DS₂-VASc → decide whether to anticoagulate.
- Calculate HAS-BLED → identify and correct modifiable bleeding risks (not to withhold anticoagulation).
- Choose a DOAC over warfarin in nonvalvular AF unless contraindicated.
- Adjust doses for renal function, age, and body weight.
- Reassess periodically — risk scores change over time.
This is a shared conversation. Sign in to Orris to start your own chat.